可靶向的髓系炎症状态决定透明细胞肾细胞癌的疾病复发
本研究对一项高危局限性透明细胞肾细胞癌随机辅助临床试验中仅接受安慰剂治疗患者的236个肿瘤进行全转录组分析,发现髓系来源的IL6是关键介质,髓系基因特征与疾病复发和总生存强烈相关并与TP53失活相关,而效应T细胞特征与复发无关;在免疫健全的Tp53失活小鼠模型中靶向髓系炎症可显著减少转移。
要点
- 髓系来源的IL6是局限性透明细胞肾细胞癌复发的关键介质。
- 髓系基因特征与疾病复发和总生存强烈相关,并与TP53失活相关。
- 效应T细胞基因特征、浸润模式和耗竭标志物与疾病复发无关。
核心结论
- 研究提示髓系炎症促进透明细胞肾细胞癌疾病复发且可靶向,并提供基于生物标志物的框架用于未来免疫肿瘤试验设计。
研究设计与样本
- 对一项高危局限性透明细胞肾细胞癌随机辅助临床试验中仅接受安慰剂治疗患者的236个肿瘤进行全转录组分析。
- 在新型免疫健全的Tp53失活小鼠模型中使用腺苷A2A受体拮抗剂靶向免疫抑制性髓系炎症。
主要发现
- 无偏通路分析确定髓系来源的IL6为关键介质。
- 新型髓系基因特征在单因素和多因素分析中与疾病复发和总生存强烈相关,并在多个数据集中与TP53失活相关。
- 效应T细胞基因特征、浸润模式和耗竭标志物与疾病复发无关。
- 在免疫健全的Tp53失活小鼠模型中,使用腺苷A2A受体拮抗剂靶向免疫抑制性髓系炎症显著减少转移发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: It is poorly understood how the tumor immune microenvironment influences disease recurrence in localized clear-cell renal cell carcinoma (ccRCC). Here we performed whole-transcriptomic profiling of 236 tumors from patients assigned to the placebo-only arm of a randomized, adjuvant clinical trial for high-risk localized ccRCC. Unbiased pathway analysis identified myeloid-derived IL6 as a key mediator. Furthermore, a novel myeloid gene signature strongly correlated with disease recurrence and overall survival on uni- and multivariate analyses and is linked to TP53 inactivation across multiple data sets. Strikingly, effector T-cell gene signatures, infiltration patterns, and exhaustion markers were not associated with disease recurrence. Targeting immunosuppressive myeloid inflammation with an adenosine A2A receptor antagonist in a novel, immunocompetent, Tp53-inactivated mouse model significantly reduced metastatic development. Our findings suggest that myeloid inflammation promotes disease recurrence in ccRCC and is targetable as well as provide a potential biomarker-based framework for the design of future immuno-oncology trials in ccRCC. SIGNIFICANCE: Improved understanding of factors that influence metastatic development in localized ccRCC is greatly needed to aid accurate prediction of disease recurrence, clinical decision-making, and future adjuvant clinical trial design. Our analysis implicates intratumoral myeloid inflammation as a key driver of metastasis in patients and a novel immunocompetent mouse model. This article is highlighted in the In This Issue feature, p. 2221.
引用
- Rappold PM, Vuong L, Leibold J, et al. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022. PMID: 35758895. doi:10.1158/2159-8290.CD-21-0925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。